<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04027803</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-148-3</org_study_id>
    <nct_id>NCT04027803</nct_id>
  </id_info>
  <brief_title>Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®</brief_title>
  <official_title>A Double-blind, Randomized Clinical Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-blind, Randomized Clinical Study to Compare the Pharmacokinetics, Pharmacodynamics,
      Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 (JSC BIOCAD, Russia) and
      Soliris® in Healthy Volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 21, 2018</start_date>
  <completion_date type="Actual">April 7, 2019</completion_date>
  <primary_completion_date type="Actual">April 7, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-∞ of Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>AUC0-∞ of eculizumab (the area under the Concentration vs. Time curve from 0 to infinity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>Cmax of eculizumab (maximum concentration of eculizumab in the serum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Тmax of Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>Тmax of eculizumab (time to Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-1392 of Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>AUC0-1392 of eculizumab (the area under the Concentration vs. Time curve from 0 to 1392 h post-infusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Т1/2 of Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>Т1/2 of eculizumab (half-life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd of Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>Vd of eculizumab (steady-state volume of distribution)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Кel of Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>Кel of eculizumab (elimination constant)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cl of Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>Cl of eculizumab (clearance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABEC(0-1392) CH50</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>ABEC(0-1392) CH50 (the area between the baseline and effect curves for hemolytic activity of serum complement from 0 to 1392 h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUEC(0-1392) CH50</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>AUEC(0-1392) CH50 ((area under the Time vs. Effect curve from 0 to 1392 h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emin CH50</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>Emin CH50 (minimum hemolytic complement activity from 0 to 1392 h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmin CH50</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>Tmin CH50 (time to minimum hemolytic complement activity within the period from 0 to 1392 h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With AEs/SAEs Related to Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>The percentage of subjects with AEs/SAEs that, in the investigator's opinion, are related to eculizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects Who Develop Grade 3/4 AEs Related to Eculizumab</measure>
    <time_frame>from 0 to 1392 hours post-infusion</time_frame>
    <description>• The percentage of subjects with СТСАЕ v. 4.03 grade 3/4 AEs that, in the investigator's opinion, are related to eculizumab, by study arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>BCD-148</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>39 healthy subjects received BCD-148, 900 mg, a single drip infusion over 25-45 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soliris</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>39 healthy subjects received Soliris, 900 mg, a single drip infusion over 25-45 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BCD-148</intervention_name>
    <description>single intravenous infusion of BCD-148 (900 mg)</description>
    <arm_group_label>BCD-148</arm_group_label>
    <other_name>eculizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Soliris</intervention_name>
    <description>single intravenous infusion of Soliris (900 mg)</description>
    <arm_group_label>Soliris</arm_group_label>
    <other_name>eculizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed ICF for participation in the study

          2. Men from 18 to 45 years old (inclusive) at the time of signing the ICF

          3. BMI within the normal limits (18.0 to 30 kg/m2)

          4. The subject is able to follow the Protocol procedures (in the investigator's opinion)

          5. The subject is verified as &quot;Healthy&quot; according to results of standard clinical,
             laboratory and instrumental tests

          6. Normal hemodynamic parameters: systolic BP from 90 mmHg to 130 mmHg; diastolic BP from
             60 mmHg to 90 mmHg; HR from 60 bpm to 90 bpm

          7. The subject and his sex partner of childbearing potential consent to implement
             reliable contraceptive methods from the moment the subject signs the ICF and until the
             subject completes the study. This requirement does not apply to those subjects who had
             undergone surgical sterilization. Reliable contraception methods mean one barrier
             method in combination with one of the following: spermicides, intrauterine device
             and/or oral contraceptives used by the subject's partner.

          8. The subject agrees not to drink alcohol for 24 h prior to the infusion of the
             test/reference drug and for the entire period while the subject is in the study.

             -

        Exclusion Criteria:

          1. Psychiatric disorders or other conditions that can affect the ability of the subject
             to follow the study protocol

          2. Acute infections within 4 weeks before signing the ICF

          3. Results of laboratory and/or instrumental tests are outside the site's normal range

          4. Any surgery done within 30 days before the screening or planned within 30 days after
             the subject completes the study

          5. Impossibility to insert an intravenous catheter for blood collection (e.g., because of
             a skin condition at the venipuncture site)

          6. A history of allergies

          7. Known hypersensitivity to any component of BCD-148 or Soliris®, murine proteins or
             other drug components; hypersensitivity to any component of the meningococcal vaccine

          8. The subject had used any medications that significantly affect hemodynamics, liver
             function, etc. (barbiturates, omeprazole, cimetidine, etc.) within 30 days before
             signing the ICF and/or the subject needs any medications (other than the study drugs)
             to be taken during the entire study period

          9. The subject had previously used eculizumab and/or other therapeutic monoclonal
             antibodies against complement C5

         10. Regular use (oral or parenteral) of any drugs, including OTC products, vitamins or
             biologically active supplements within 14 calendar days before signing the ICF

         11. A history of recurrent/chronic hemorrhages or any hemorrhage within 30 days prior to
             signing the ICF

         12. Acute or chronic infections or other diseases that, in the investigator's opinion, may
             affect the PK, PD or safety of the study products

         13. HIV, HCV, HBV infection, syphilis.

         14. Meningococcal infection in the past (documented or mentioned verbally by the subject)

         15. Vaccination within 4 weeks before the planned infusion date, except for vaccination
             against Neisseria meningitidis given to all subjects in the screening period

         16. The subject refuses to get a vaccination against Neisseria meningitidis during the
             screening period .

         17. The subject smokes more than 10 cigarettes per day

         18. The subject consumes more than 10 units of alcohol per week (1 unit equals to 0.5 L of
             beer, 200 mL of wine or 50 mL of a strong alcohol beverage) or has a history of
             alcohol, recreational drug or medication abuse, or tests positive for alcohol and/or
             psychoactive substances during the screening examination

         19. Donation of ≥ 450 mL of blood or plasma within 60 calendar days before signing the
             ICF.

         20. Participation in any drug clinical studies within 30 calendar days prior to signing
             the informed consent form and through the entire period of study participation.

             -
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Limited Liability Company Research Center Eco-Bezopasnost (OOO Research Center Eco-Bezopasnost)</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 16, 2019</study_first_submitted>
  <study_first_submitted_qc>July 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2019</study_first_posted>
  <results_first_submitted>January 13, 2020</results_first_submitted>
  <results_first_submitted_qc>May 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 15, 2020</results_first_posted>
  <last_update_submitted>May 3, 2020</last_update_submitted>
  <last_update_submitted_qc>May 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT04027803/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BCD-148</title>
          <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
        </group>
        <group group_id="P2">
          <title>Soliris</title>
          <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BCD-148</title>
          <description>39 healthy subjects BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
        </group>
        <group group_id="B2">
          <title>Soliris</title>
          <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="24" upper_limit="32"/>
                    <measurement group_id="B2" value="27" lower_limit="24" upper_limit="32"/>
                    <measurement group_id="B3" value="27" lower_limit="24" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="39"/>
                    <count group_id="B3" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞ of Eculizumab</title>
        <description>AUC0-∞ of eculizumab (the area under the Concentration vs. Time curve from 0 to infinity)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞ of Eculizumab</title>
          <description>AUC0-∞ of eculizumab (the area under the Concentration vs. Time curve from 0 to infinity)</description>
          <units>(ng/ml)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104346442.41" lower_limit="86711718.872" upper_limit="138234664.3"/>
                    <measurement group_id="O2" value="114291981.79" lower_limit="95801210.959" upper_limit="126281914.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Eculizumab</title>
        <description>Cmax of eculizumab (maximum concentration of eculizumab in the serum)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Eculizumab</title>
          <description>Cmax of eculizumab (maximum concentration of eculizumab in the serum)</description>
          <units>ng/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102466648.13" lower_limit="86216316.914" upper_limit="130773188.67"/>
                    <measurement group_id="O2" value="112710712.24" lower_limit="95318606.352" upper_limit="125562084.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Тmax of Eculizumab</title>
        <description>Тmax of eculizumab (time to Cmax)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Тmax of Eculizumab</title>
          <description>Тmax of eculizumab (time to Cmax)</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" lower_limit="4" upper_limit="12"/>
                    <measurement group_id="O2" value="8" lower_limit="0.083" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-1392 of Eculizumab</title>
        <description>AUC0-1392 of eculizumab (the area under the Concentration vs. Time curve from 0 to 1392 h post-infusion)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-1392 of Eculizumab</title>
          <description>AUC0-1392 of eculizumab (the area under the Concentration vs. Time curve from 0 to 1392 h post-infusion)</description>
          <units>(ng/ml)*hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102466648.13" lower_limit="86216316.914" upper_limit="130773188.67"/>
                    <measurement group_id="O2" value="112710712.24" lower_limit="95318606.352" upper_limit="125562084.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Т1/2 of Eculizumab</title>
        <description>Т1/2 of eculizumab (half-life)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Т1/2 of Eculizumab</title>
          <description>Т1/2 of eculizumab (half-life)</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.429" lower_limit="154.479" upper_limit="198.042"/>
                    <measurement group_id="O2" value="161.61" lower_limit="132.711" upper_limit="209.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vd of Eculizumab</title>
        <description>Vd of eculizumab (steady-state volume of distribution)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Vd of Eculizumab</title>
          <description>Vd of eculizumab (steady-state volume of distribution)</description>
          <units>ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2595.302" lower_limit="2118.734" upper_limit="3434.689"/>
                    <measurement group_id="O2" value="2620.503" lower_limit="1973.187" upper_limit="2984.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Кel of Eculizumab</title>
        <description>Кel of eculizumab (elimination constant)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Кel of Eculizumab</title>
          <description>Кel of eculizumab (elimination constant)</description>
          <units>1/h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" lower_limit="0.004" upper_limit="0.004"/>
                    <measurement group_id="O2" value="0.004" lower_limit="0.003" upper_limit="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cl of Eculizumab</title>
        <description>Cl of eculizumab (clearance)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Cl of Eculizumab</title>
          <description>Cl of eculizumab (clearance)</description>
          <units>ml/(h*kg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.783" lower_limit="6.882" upper_limit="10.439"/>
                    <measurement group_id="O2" value="7.985" lower_limit="7.168" upper_limit="9.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ABEC(0-1392) CH50</title>
        <description>ABEC(0-1392) CH50 (the area between the baseline and effect curves for hemolytic activity of serum complement from 0 to 1392 h)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>ABEC(0-1392) CH50</title>
          <description>ABEC(0-1392) CH50 (the area between the baseline and effect curves for hemolytic activity of serum complement from 0 to 1392 h)</description>
          <units>(%)*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33606.865" lower_limit="-51185.201" upper_limit="-20772.736"/>
                    <measurement group_id="O2" value="-37244.026" lower_limit="-49459.807" upper_limit="-25247.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUEC(0-1392) CH50</title>
        <description>AUEC(0-1392) CH50 ((area under the Time vs. Effect curve from 0 to 1392 h)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>AUEC(0-1392) CH50</title>
          <description>AUEC(0-1392) CH50 ((area under the Time vs. Effect curve from 0 to 1392 h)</description>
          <units>(%)*h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61600.835" lower_limit="45529.369" upper_limit="75529.787"/>
                    <measurement group_id="O2" value="53479.141" lower_limit="40111.132" upper_limit="72474.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emin CH50</title>
        <description>Emin CH50 (minimum hemolytic complement activity from 0 to 1392 h)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Emin CH50</title>
          <description>Emin CH50 (minimum hemolytic complement activity from 0 to 1392 h)</description>
          <units>% of hemolitic activity</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmin CH50</title>
        <description>Tmin CH50 (time to minimum hemolytic complement activity within the period from 0 to 1392 h)</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Tmin CH50</title>
          <description>Tmin CH50 (time to minimum hemolytic complement activity within the period from 0 to 1392 h)</description>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" lower_limit="0.083" upper_limit="0.083"/>
                    <measurement group_id="O2" value="0.083" lower_limit="0.083" upper_limit="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With AEs/SAEs Related to Eculizumab</title>
        <description>The percentage of subjects with AEs/SAEs that, in the investigator's opinion, are related to eculizumab</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With AEs/SAEs Related to Eculizumab</title>
          <description>The percentage of subjects with AEs/SAEs that, in the investigator's opinion, are related to eculizumab</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects Who Develop Grade 3/4 AEs Related to Eculizumab</title>
        <description>• The percentage of subjects with СТСАЕ v. 4.03 grade 3/4 AEs that, in the investigator's opinion, are related to eculizumab, by study arms.</description>
        <time_frame>from 0 to 1392 hours post-infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BCD-148</title>
            <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
          <group group_id="O2">
            <title>Soliris</title>
            <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects Who Develop Grade 3/4 AEs Related to Eculizumab</title>
          <description>• The percentage of subjects with СТСАЕ v. 4.03 grade 3/4 AEs that, in the investigator's opinion, are related to eculizumab, by study arms.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>82 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BCD-148</title>
          <description>39 healthy subjects/ BCD-148: single 900 mg drip infusion given over 25-45 min
BCD-148: single intravenous infusion of 900 mg BCD-148 active substance of BCD-148 is eculizumab - a monoclonal antibody that targets complement protein C5</description>
        </group>
        <group group_id="E2">
          <title>Soliris</title>
          <description>39 healthy subjects Soliris: single 900 mg drip infusion given over 25-45 min
Soliris: single intravenous infusion of 900 mg BCD-148 active substance of Soliris is eculizumab - a monoclonal antibody that targets complement protein C5</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>eosinophils count increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>lymphocytosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>monocytes count increase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>platelet count decrease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ESR increase</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INR decrease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>prothrombin time decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>prothrombin time increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Morozova Maria</name_or_title>
      <organization>BIOCAD</organization>
      <phone>+7 (495) 992 66 28 ext 8436</phone>
      <email>morozovama@biocad.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

